vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Phoenix Education Partners, Inc. (PXED). Click either name above to swap in a different company.
Phoenix Education Partners, Inc. is the larger business by last-quarter revenue ($222.5M vs $177.4M, roughly 1.3× Pacira BioSciences, Inc.). Phoenix Education Partners, Inc. runs the higher net margin — 4.8% vs 1.6%, a 3.2% gap on every dollar of revenue.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
The University of Phoenix (UoPX) is a private for-profit university headquartered in Phoenix, Arizona. Founded in 1976, the university confers certificates and degrees at the certificate, associate, bachelor's, master's, and doctoral degree levels. It is institutionally accredited by the Higher Learning Commission and has an open enrollment admissions policy for many undergraduate programs. The school is owned by Phoenix Education Partners.
PCRX vs PXED — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $222.5M |
| Net Profit | $2.9M | $10.8M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 6.3% |
| Net Margin | 1.6% | 4.8% |
| Revenue YoY | 5.0% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.07 | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $222.5M | ||
| Q4 25 | $196.9M | $262.0M | ||
| Q3 25 | $179.5M | — | ||
| Q2 25 | $181.1M | — | ||
| Q1 25 | $168.9M | — | ||
| Q4 24 | $187.3M | — | ||
| Q3 24 | $168.6M | — | ||
| Q2 24 | $178.0M | — |
| Q1 26 | $2.9M | $10.8M | ||
| Q4 25 | — | $15.5M | ||
| Q3 25 | $5.4M | — | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $4.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | — | ||
| Q2 24 | $18.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | 6.3% | ||
| Q4 25 | 1.2% | 9.8% | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 4.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | -82.8% | — | ||
| Q2 24 | 15.9% | — |
| Q1 26 | 1.6% | 4.8% | ||
| Q4 25 | — | 5.9% | ||
| Q3 25 | 3.0% | — | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | — | ||
| Q2 24 | 10.6% | — |
| Q1 26 | $0.07 | $0.28 | ||
| Q4 25 | $0.05 | $0.40 | ||
| Q3 25 | $0.12 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.10 | — | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $-3.11 | — | ||
| Q2 24 | $0.39 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $201.4M |
| Total DebtLower is stronger | — | $58.8M |
| Stockholders' EquityBook value | $653.9M | $291.1M |
| Total Assets | $1.2B | $546.4M |
| Debt / EquityLower = less leverage | — | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $201.4M | ||
| Q4 25 | $238.4M | $163.5M | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
| Q1 26 | — | $58.8M | ||
| Q4 25 | $372.2M | $61.6M | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | $291.1M | ||
| Q4 25 | $693.1M | $280.4M | ||
| Q3 25 | $727.2M | — | ||
| Q2 25 | $757.8M | — | ||
| Q1 25 | $798.5M | — | ||
| Q4 24 | $778.3M | — | ||
| Q3 24 | $749.6M | — | ||
| Q2 24 | $879.3M | — |
| Q1 26 | $1.2B | $546.4M | ||
| Q4 25 | $1.3B | $549.6M | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | — |
| Q1 26 | — | 0.20× | ||
| Q4 25 | 0.54× | 0.22× | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $48.9M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 19.6% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 4.53× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $48.9M | ||
| Q4 25 | $43.7M | $31.1M | ||
| Q3 25 | $60.8M | — | ||
| Q2 25 | $12.0M | — | ||
| Q1 25 | $35.5M | — | ||
| Q4 24 | $33.1M | — | ||
| Q3 24 | $53.9M | — | ||
| Q2 24 | $53.2M | — |
| Q1 26 | — | $43.5M | ||
| Q4 25 | $43.5M | $26.4M | ||
| Q3 25 | $57.0M | — | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | — | ||
| Q2 24 | $51.6M | — |
| Q1 26 | — | 19.6% | ||
| Q4 25 | 22.1% | 10.1% | ||
| Q3 25 | 31.7% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | — | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 29.0% | — |
| Q1 26 | — | 2.4% | ||
| Q4 25 | 0.1% | 1.8% | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 0.9% | — |
| Q1 26 | — | 4.53× | ||
| Q4 25 | — | 2.01× | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PXED
Segment breakdown not available.
